Lessons from a Severe Case of Fulminant Guillain-Barré Syndrome: A Case Report.

Reports (MDPI) · 2026 · PMC13214634 · PMID 42200842

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Emerging targeted therapies remain investigational; in a phase 3 randomized trial, eculizumab added to IVIG did not achieve the primary efficacy endpoint and key secondary endpoints did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.